|Home | About | Journals | Submit | Contact Us | Français|
Response monitoring abnormalities have been reported in chronic schizophrenia patients, but it is unknown whether they predate the onset of psychosis, are present in early stages of illness, or are late-developing abnormalities associated with illness progression. Response-synchronized event-related potentials (ERP) recorded during a picture-word matching task yielded error-related negativity (ERN), correct-response negativity (CRN), and error positivity (Pe) from 84 schizophrenia patients (SZ), 48 clinical high risk patients (CHR), and their age-matched healthy controls (HC; n = 110 and 88, respectively). A sub-sample of 35 early illness schizophrenia patients (ESZ) was compared to 93 age-matched HC and the CHR patients (after statistically removing the effects of normal aging). Relative to HC, 1) SZ, ESZ, and CHR had smaller ERNs, and 2) SZ and ESZ had larger CRNs and smaller Pes. Within the SZ, longer illness duration was associated with larger CRNs but was unrelated to ERN or Pe. CHR and ESZ did not differ on ERN or CRN, although Pe was smaller in ESZ than CHR. These results indicate that while ERN, CRN, and Pe abnormalities are present early in the illness, only the ERN abnormality is evident prior to psychosis onset, and only the CRN abnormality appears to worsen progressively over the illness course. Brain regions subserving response monitoring may be compromised early in the illness and possibly during its clinical prodrome.
Successful performance of cognitive tasks requires the online monitoring of our own responses in order to detect errors and to make strategic adjustments to enhance accuracy. The brain’s error-monitoring system is reflected by the error-related negativity (ERN) (Falkenstein, Hohnsbein, Hoorman, & Blanke, 1990; Gehring, Goss, Coles, Meyer, & Donchin, 1993) and the error positivity (Pe; Falkenstein, Hoormann, Christ, & Hohnsbein, 2000; Mathalon et al., 2002; Nieuwenhuis, Ridderinkhof, Blom, Band, & Kok, 2001), two event-related potential (ERP) components, successively elicited by commission errors across a wide variety of choice reaction-time tasks. Patients with schizophrenia have been shown to exhibit behavioral impairments in performance monitoring during cognitive tasks (Blakemore, Smith, Steel, Johnstone, & Frith, 2000; Malenka, Angel, Hampton, & Berger, 1982; Turken, Vuilleumier, Mathalon, Swick, & Ford, 2003), likely contributing to their deficits in performance accuracy. In regard to neurophysiology, schizophrenia has been associated with abnormal reduction of ERN amplitude in response to errors (Alain, McNeely, He, Christensen, & West, 2002; Bates, Kiehl, Laurens, & Liddle, 2002; Bates, Liddle, Kiehl, & Ngan, 2004; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Mathalon, Jorgensen, Roach, & Ford, 2009; Morris, Heerey, Gold, & Holroyd, 2008; Morris, Yee, & Nuechterlein, 2006) as well as an abnormally enlarged ERN-like negativity following correct trials known as the correct-response negativity (CRN; Alain et al., 2002; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Morris et al., 2008; Morris et al., 2006). Although these electrophysiological abnormalities are evident in schizophrenia patients independent of clinical severity (Bates et al., 2004), it remains unclear whether they are present early in the illness, or indeed, whether they are present in individuals at clinical high risk for the development of psychosis.
The error-related negativity (ERN) (Gehring et al., 1993), or error negativity (Ne; Falkenstein et al., 1990), component of the response-locked ERP associated with performance errors in speeded choice-response tasks is evident following the earliest electromyographic activity generated by overt error responses (Gehring, Coles, Meyer, & Donchin, 1995; Kopp & Rist, 1999; Kopp, Rist, & Mattler, 1996) and peaks 50–150 ms after the error is committed. Larger (i.e., more negative) ERNs are associated with instructions emphasizing accuracy over speed, faster errors, lower error rates, attempts to correct errors, greater post-error slowing, and greater error salience (Bernstein, Scheffers, & Coles, 1995; Falkenstein et al., 2000; Gehring et al., 1995; Scheffers & Coles, 2000). Topographic scalp maps show the ERN to have a fronto-central maximum (Falkenstein, Hohnsbein, Hoormann, & Blanke, 1991; Gehring et al., 1995). Converging evidence from dipole modeling of the ERN (Badgaiyan & Posner, 1998; Dehaene, Posner, & Tucker, 1994; Holroyd, Dien, & Coles, 1998; Luu, Flaisch, & Tucker, 2000; Milter, Braun, & Coles, 1997), functional magnetic resonance imaging (fMRI; Carter et al., 1998; Kiehl, Liddle, & Hopfinger, 2000; Mathalon et al., 2009; Mathalon, Whitfield, & Ford, 2003; van Veen & Carter, 2002), and intracranial recordings from monkeys (Brooks, 1987; Gemba, Sasaki, & Brooks, 1986; Niki & Watanabe, 1979), suggests that anterior cingulate cortex (ACC) is the principal generator of the ERN. The ERN has variously been considered by researchers to reflect simple error detection (Falkenstein et al., 1991; Gehring et al., 1993; Gehring et al., 1995; Hohnsbein, Falkenstein, Hoormann, & Blanke, 1991), high levels of response conflict (Danielmeier, Wessel, Steinhauser, & Ullsperger, 2009; Gehring & Fencsik, 2001; Hughes & Yeung, 2010; van Veen & Carter, 2002), but see (Carbonnell & Falkenstein, 2006; Masaki, Falkenstein, Sturmer, Pinkpank, & Sommer, 2007), and reward prediction errors in which outcomes are worse than expected (Holroyd & Coles, 2002). It is interesting that the ERN is evoked by errors committed outside of conscious awareness (Endrass, Reuter, & Kathmann, 2007; Nieuwenhuis et al., 2001; O’Connell, et al., 2007).
There is often a small fronto-central ERN-like negativity following correct responses known as the correct-response negativity (CRN; Falkenstein et al., 2000; Gehring & Knight, 2000; Scheffers & Coles, 2000; Scheffers, Coles, Bernstein, Gehring, & Donchin, 1996; Vidal, Hasbroucq, Grapperon, & Bonnet, 2000). As reviewed by Coles et al. (Coles, Scheffers, & Holroyd, 2001), CRNs may result when subjects: 1) detect partial errors, 2) exhaust the allotted time for a given response, 3) lack confidence that a correct response was made, or 4) experience high response conflict. Alternatively, it has been proposed that some CRN activity may be present on all responses, reflecting the response checking or monitoring process itself, with the ERN superimposed on the CRN when the outcome of this monitoring process is the detection of an error (Falkenstein et al., 2000).
The error positivity (Pe) is a positive voltage response-locked ERP component with a centro-parietal scalp maximum appearing 200–500 ms following error responses (Falkenstein et al., 1990; Falkenstein, Hohnsbein, & Hoormann, 1995; Falkenstein et al., 1991; Falkenstein et al., 2000; Scheffers & Coles, 2000; Vidal et al., 2000). The Pe has been localized to the rostral ACC and superior parietal cortex, as opposed to the more caudal ACC source of the ERN (Herrmann, Rommler, Ehlis, Heidrich, & Fallgatter, 2004; van Veen & Carter, 2002). Unlike the ERN, awareness of errors is necessary to produce a Pe (Endrass et al., 2007; Hughes & Yeung, 2011; Nieuwenhuis et al., 2001; O’Connell, et al., 2007). Indeed, the Pe may be a P300-like positivity resulting from context updating when errors are consciously recognized (Falkenstein et al., 1991; Leuthold & Sommer, 1999) and response strategies are adjusted (Falkenstein et al., 1995).
Studies of error monitoring in schizophrenia have repeatedly demonstrated ERN amplitude reduction (Alain et al., 2002; Bates et al., 2002; Bates et al., 2004; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Mathalon et al., 2009; Morris et al., 2008; Morris et al., 2006). In addition, some (Alain et al., 2002; Mathalon et al., 2002; Morris et al., 2008; Morris et al., 2006), but not all (Bates et al., 2002; Bates et al., 2004; Mathalon et al., 2009) studies have reported abnormally large CRNs in schizophrenia. Many studies have shown schizophrenia patients to have normal Pe amplitudes (Alain et al., 2002; Bates et al., 2004; Kim et al., 2006; Mathalon et al., 2002; Morris et al., 2006) and normal post-error slowing (Bates et al., 2002; Bates et al., 2004; Mathalon et al., 2002) following errors, suggesting that their ERN and CRN abnormalities are not simply the result of deficient error awareness. Some (Carter, MacDonald, Ross, & Stenger, 2001; Kerns et al., 2005; Laurens, Ngan, Bates, Kiehl, & Liddle, 2003; Polli et al., 2008), but not all (Mathalon et al., 2009), fMRI studies suggest that the ACC is hypoactive in response to errors in schizophrenia, consistent with other evidence of functional (Minzenberg, Laird, Thelen, Carter, & Glahn, 2009) and structural abnormalities (Benes, 1993; Benes & Bird, 1987) in the ACC. Although error monitoring has been repeatedly studied in chronic schizophrenia patients, it has not been examined in patients early in their illness, or in putatively prodromal patients at clinical high risk for psychosis. Accordingly, it remains unclear whether the ERN/CRN abnormalities observed in schizophrenia patients predate the onset of psychosis, are present in early stages of illness, or are late-developing abnormalities associated with illness progression and/or nonspecific aspects of illness chronicity.
In the past decade, clinical criteria have been developed to identify individuals exhibiting a prodromal syndrome associated with increased risk for psychosis. These include the Criteria of Prodromal Syndromes (COPS; Miller et al., 2002) and the similar At-Risk Mental States criteria (ARMS; Yung & McGorry, 1996). Validation studies show these criteria to predict conversion to full-blown psychosis, most often schizophrenia (Woods et al., 2009), at a rate of 35% over a 2.5-year follow-up period (Cannon et al., 2008). Thus, about two-thirds of the individuals meeting clinical criteria for this psychosis risk syndrome do not convert to psychosis, limiting the potential for early intervention with these clinical high risk patients. This limitation has motivated recent and ongoing studies aimed at determining whether the neurobiological abnormalities associated with schizophrenia are present prior to psychosis onset (Brockhaus–Dumke et al., 2008; Karlsgodt et al., 2008; van der Stelt, Lieberman, & Belger, 2005), potentially enhancing our ability to predict future risk for psychosis and setting the stage for targeted preventive interventions.
Many of the individuals at clinical high risk for psychosis are adolescents and young adults, underscoring the need to take normal brain maturational processes into account when examining neurobiological markers such as the ERN. Segalowitz (Davies, Segalowitz, & Gavin, 2004; Mathewson, Dywan, & Segalowitz, 2005; Santesso & Segalowitz, 2008; Santesso, Segalowitz, & Schmidt, 2006) and others (Ladouceur, Dahl, & Carter, 2004) have shown ERN amplitudes to increase from childhood to young adulthood, whereas the CRN has been shown to increase from about age 10 to 16 years, leveling off thereafter (Davies et al., 2004). In contrast, the centro-parietal Pe was generally stable over this same developmental period (Davies et al., 2004; Ladouceur et al., 2004; Santesso et al., 2006). Thus, the various neurophysiological signals associated with performance monitoring show distinct neurodevelopmental trajectories from childhood to early adulthood. Segalowitz and colleagues (Segalowitz, Santesso, & Jetha, 2010) suggest that these data are indicative of late maturation of the ACC and/or late involvement of the ACC during performance monitoring.
In the current study, the ERN, CRN, and Pe elicited during a picture–word verification task were assessed in patients with schizophrenia across the illness course, including a subsample of early illness patients assessed within 2 years of their first psychiatric hospitalization for psychosis, and in patients at clinical high risk for psychosis. Each group was compared to a group of age-matched healthy control subjects, and after removing the effects of normal aging, the early illness schizophrenia and clinical high risk patients were directly compared. Based on the hypothesis that electrophysiological abnormalities associated with error monitoring are a core pathophysiological feature of schizophrenia, we predicted that patients early in their illness course would show an attenuated ERN, an increased CRN, and a normal Pe, similar to our prior observations in chronic patients (Mathalon et al., 2002). Additionally, positing that these electrophysiological abnormalities reflect either genetic vulnerability for schizophrenia or result from faulty neurodevelopment, we hypothesized that this pattern of abnormalities would be evident in patients at clinical high risk for psychosis, albeit in attenuated form, given that only a subset of these patients will ultimately convert to schizophrenia. Moreover, since the clinical high risk patients have not been exposed to antipsychotic medication, study of this group provides an opportunity to assess whether these performance-related ERP components are abnormal in the absence of the antipsychotic confound associated with studies of schizophrenia patients. Furthermore, in order to examine progression over the illness course, we asked whether the degree of abnormality present in each ERP component, relative to values expected based on normal aging, is correlated with illness duration across the full schizophrenia sample.
Study participants included 50 patients at clinical high risk (CHR) for psychosis based on the Structured Interview for Prodromal Syndromes (Miller et al., 2003; Miller et al., 2002), 88 patients with schizophrenia (SZ; per the Diagnostic and Statistical Manual of Mental Disorders–IV) based on the Structured Clinical Interview for DSM–IV (SCID), and 135 healthy control (HC) subjects. CHR patients met criteria for at least one of the three subsyndromes defined by the COPS (Miller et al., 2003; Miller et al., 2002): 1) attenuated positive symptoms (APS); 2) brief intermittent psychotic states (BIPS); 3) genetic risk with deterioration in social/occupational functioning (GRD). Among the SZ, a sub-sample of 38 patients were identified as early illness (ESZ), defined as being within 2 years of initial hospitalization for psychosis or initiation of antipsychotic medication. Interviews were conducted by a trained research assistant, psychiatrist, or clinical psychologist.
Out of the 135 HC subjects, three overlapping age-matched groups were organized according to the age range of each patient group: 1) a group of 115 healthy controls (age range 16–59 years) age-matched to SZ patients; 2) a group of 96 healthy controls (age range 16–37 years) age-matched to ESZ patients; and 3) a group of 92 healthy controls (age range 12–28 years) age-matched to CHR patients.
Patients were referred by community clinicians. HC participants were recruited by advertisements and word of mouth. Exclusion criteria for the HC group included a past or current DSM–IV major Axis I disorder based on a SCID interview or having a first-degree relative with a psychotic disorder. Exclusion criteria for all groups included a history of illicit substance dependence or substance abuse within the past year, a history of significant medical or neurological illness, or a history of head injury resulting in loss of consciousness. The study was approved by the institutional review boards of the University of California, San Francisco and Yale University, and all adult participants provided written informed consent. In the case of minor participants, parents provided written informed consent and youths provided written informed assent. Clinical and demographic data for all groups are presented in Table 1.
Within 4 weeks of ERP assessment (mean [M] = 12.51, standard deviation [SD] = 17.7 days), a clinically trained research assistant, psychiatrist, or clinical psychologist rated schizophrenia symptoms using the Positive and Negative Syndrome Scale (PANSS; Kay & Opler, 1987). Prodromal symptoms were rated using the Scale of Prodromal Symptoms (SOPS; Miller et al., 2003; Miller et al., 2002).
A variant of our earlier picture–word verification task (Mathalon et al., 2002) was used. In this task, each trial consists of consecutive presentations of a picture for 250 ms, a blank screen for 75 ms, and a word for 250 ms. Subjects are instructed to indicate whether or not the word matched the preceding picture by pressing one of two buttons. The pictures consisted of 102 line drawings, selected for nameability from a set of 120 (Snodgrass & Vanderwart, 1980) based on pilot testing in young adults. Pictures were classified into 10 natural categories (clothing, animal, bird, appliance, tool, vehicle, vegetable, fruit, toy, and musical instrument). The full set of pictures was presented in each of four blocks. Pictures were paired with different words in the different blocks, and the order of the pictures was varied across blocks. The inter-stimulus interval between successive trials was jittered between 1,625 ms and 3,225 ms.
Each picture was paired with a word that either matched (50%) or did not match (50%) the picture. Of those that did not match, half (25%) were words within the category and half (25%) were outside the category. For example, a picture of a camel was followed by the word “camel” (match), by “cow” (in category non-match), or by “candle” (out of category non-match). Subjects pressed buttons with right and left index fingers to indicate whether or not the word matched the picture. Subjects pressed one button to matches and the other button to nonmatches, with hand of press counterbalanced across subjects. Prior to starting the task, participants listened to recorded instructions that emphasized both response speed and accuracy and completed a 20-trial practice session to ensure task comprehension. In order to assess ERPs associated with performance accuracy (errors vs. correct responses) using the maximum number of trials, trials were collapsed across the various match/nonmatch conditions.
Electroencephalographic (EEG) data were recorded from 64 scalp sites using a BioSemi ActiveTwo system (www.biosemi.com). EEG data were continuously digitized at 1024 Hz, referenced offline to averaged earlobe electrodes, and digitally bandpass-filtered between 0.5 and 12 Hz. Continuous data were separated into 850 ms epochs time-locked to the button-press response, encompassing 100 ms before and 750 ms after the response. Electrodes placed at the outer canthi of both eyes and above and below the right eye recorded vertical and horizontal electrooculogram data, which were used in a regression-based algorithm (Gratton, Coles, & Donchin, 1983) to correct EEG epochs for eye movements and blinks.
EEG epochs were baseline-corrected relative to the 100 ms pre-response baseline and artifact rejected for voltages exceeding ± 50 μV in nine central electrodes (F3, Fz, F4, C3, Cz, C4, P3, Pz, P4). For both error and correct responses, epochs surviving artifact rejection were averaged to form individual participant error and correct ERP waveforms. Grand average ERP waveforms were then produced from these individual averages. Based on reports regarding stability of the ERN component (Olvet & Hajcak, 2009; Pontifex et al., 2010), individuals had to have a minimum of n = 6 error trials to be included in the analyses.
The ERN and CRN were measured as the most negative peaks between 0 ms and 125 ms in each subject’s error and correct ERP waveforms, respectively. The Pe was measured as the average voltage between 200 ms and 500 ms from the error ERP waveforms. Only subjects with a discernable ERN peak (i.e., change in slope from negative to positive) in the 0 – 125 ms post-response time window were included for analysis, resulting in exclusion of six HC, two CHR, and six SZ (four of whom were also characterized as ESZ) with noisy ERPs lacking an identifiable ERN. The final samples consisted of (1) 84 SZ age-matched with 110 HC; (2) 35 ESZ age-matched with 93 HC; and 3) 48 CHR age-matched with 88 HC.
Our primary approach to controlling for the effects of normal aging when evaluating whether the patient groups showed ERP abnormalities was to compare each patient group or subgroup with an age-matched HC group. However, in order to directly compare the CHR and ESZ groups, whose ages significantly differed (p < .001), it was necessary to first remove the effects of normal brain maturation and aging from the ERP measures. To model these normal maturation/aging effects, each ERP component was regressed on age in the full sample of HC (n = 130; age range 12 to 59 years). For each ERP measure, the resulting regression equation was then used to derive age-specific predicted values for all participants (patients and HC). Differences between actual values and predicted values were then divided by the standard error (SE) of regression from the HC regression model, yielding age-corrected z-scores for each ERP component (ERN, CRN, Pe) for all subjects. This method has been used in previous brain imaging studies of patient groups to control for normal aging effects (Pfefferbaum et al., 1992) and is preferable to a standard analysis of covariance (ANCOVA) model because it only removes normal aging effects while preserving any abnormal aging effects related to the disease process. The resulting age-corrected z-scores expressed each ERP component in standard units of deviation from the value expected for a healthy individual of a given age.
Error rates were compared for each patient-control group pair with t tests for independent samples. Individual subject median reaction times (RTs) were extracted for correct and error trials. The effects of group (patients vs. controls) and accuracy (error vs. correct) on RT were assessed using a two-way analysis of variance (ANOVA) for each patient–control group pair.
To measure post-error slowing within an individual subject, the median RT for correct trials following correct trials (correct–correct) was subtracted from the median RT for correct trials following error trials (error–correct). Because the different trial types in our task were associated with RT differences (i.e., in-category nonmatch > out-of-category nonmatch > match trials), correct–correct trial pairs were pseudorandomly selected such that the relative proportions of various trial type combinations matched the proportions present among the error–correct trial pairs. Although the proportions of various trial type combinations were matched, the absolute number of correct–correct trial pairs exceeded the number of error–correct trial pairs, maximizing the number trials used to derive the correct trial median RT estimates. Post-error slowing median RT difference scores were compared between patient and HC groups using t-tests for independent samples.
For each patient–control group pair, ERN/CRN amplitudes were analyzed in a Group (patients, controls) × Accuracy (ERN, CRN) × Lead (Fz, FCz, Cz) ANOVA, and Pe amplitudes were analyzed in a Group × Lead (FCz, Cz, Pz) ANOVA. Interactions involving group were parsed with follow-up ANOVAs. Greenhouse–Geisser corrections were applied to the tests of all within-subjects factors containing more than two levels in the repeated-measures ANOVAs.
Because the CHR group was significantly younger than the ESZ group, direct comparisons of these groups were based on one-way ANOVAs of the age-corrected z-scores for each ERP component (ERN, CRN, Pe) at the lead showing the greatest patient– control differences in the raw ERP amplitude analyses. As described above, the z-scores reflected deviations in standard units from the ERP amplitudes expected for a healthy person of a given age, based on modeled normal aging effects in the full HC sample.
To assess for patient–control group differences in the relationship between behavior and ERP component amplitudes, we regressed each ERP component on the behavioral measure, group (dummy coded), and the Group × Behavioral measure interaction. The interaction term tested for slope differences between the groups. When the slope difference was not significant, the interaction term was dropped and the analysis focused on the test of the common slope estimated within both groups. The ERP components considered were the ERN, CRN, and Pe. The behavioral measures considered were error rate and post-error slowing scores.
In order to determine whether each ERP component abnormality progressively worsened over the illness course, independent of normal aging effects, duration of illness was correlated with age-corrected z-scores for ERN, CRN, and Pe, within the full SZ sample.
To assess the relationship between symptom severity and ERP component amplitudes, the amplitude of each ERP component (ERN, CRN, Pe) was correlated with positive and negative symptom subscale scores from the PANSS in the full SZ sample. Correlations of ERP component amplitudes with SOPS positive and negative symptom subscale scores were performed in the CHR group. Because of the exploratory nature of these symptom correlations, a Bonferroni correction for the number of correlations performed was applied within each patient group.
Group demographic data and analyses are presented in Table 1. Independent sample t-tests confirmed that there were no significant differences in age between each patient group and its respective age-matched control group, although the ESZ group was significantly older than the CHR group, t(81) = 3.7, p < .001. Each patient group had significantly lower parental socioeconomic status (SES; Hollingshead, 1975) than their age-matched control group, but ESZ and CHR patients did not differ from each other (p > .3). Chi-square tests showed that the full sample of SZ patients had a significantly greater proportion of males than females relative to the age-matched HC group, although gender distributions did not significantly differ between the remaining patient and matched control groups or between ESZ and CHR groups. There were no significant differences in handedness (Crovitz & Zener, 1962) between patients and their respective control groups or between ESZ and CHR groups. To address potential confounds associated with group differences in parental SES and gender, group effects on the ERP components were assessed with ANCOVA models using each of these variable as covariates.
The SZ group, ESZ subgroup, and CHR group made significantly more errors than their respective age-matched HC (Figure 1a). Error rates did not differ between CHR and ESZ (p = .18). For RT (Figure 1b), the Group × Accuracy ANOVAs for each patient–control group pairing revealed significant main effects of group [for SZ vs. HC, F(1, 192) = 61.85, p < .001; for ESZ vs. HC, F(1, 126) = 32.35, p < .001; for CHR versus HC, F(1, 134) = 7.31, p < .01] indicating that all patient groups responded more slowly than their age-matched HCs. The main effect of accuracy, F(1, 192) = 7.93, p < .005) and the Group × Accuracy interaction, F(1, 192) = 4.18, p < .05 were significant in the SZ versus HC ANOVA, but not for the other group pairings. Follow-up paired t-tests indicated significantly slower errors than correct responses in SZ, t(83) = −2.5, p < .05, but not in their age-matched HC (p = .42). All groups exhibited post-error slowing, and there were no significant pair-wise patient–control differences (Figure 1c).
As can be seen in the grand average ERP waveforms shown in Figure 2, errors elicited a large fronto-central (Fz, FCz, Cz) ERN peaking at approximately 60 ms (SD = 21.6 ms) post-response, and correct responses elicited a smaller fronto-central (Fz, FCz, Cz) CRN peaking at about 55 ms (SD = 27.6 ms) post-response. Subsequent to the ERN, a slow positive fronto-central-parietal (FCz, Cz, Pz) Pe was evident from 200 to 500 ms. Scalp topography maps for the ERN, CRN, and Pe for all of the patient and HC groups are presented in Figure 1 of the supplementary materials.
Table 2 presents the ERN/CRN ANOVA results for each patient–control group comparison. Summary plots in Figure 3a present the mean ERN and CRN amplitudes at Cz for each of the patient and HC groups. None of the ANOVA results involving group or accuracy effects were substantially changed when reanalyzed as ANCOVAs with either parental SES or gender as covariates.
For the comparison of the full sample of SZ patients with their age-matched controls, there was a significant main effect of accuracy, confirming that the amplitude of the ERN was significantly larger (more negative) than the CRN, as well as a significant main effect of lead, indicating greater overall negativity at FCz relative to Fz and Cz. In addition, there were significant Accuracy × Group and Accuracy × Group × Lead interactions, leading us to examine the Accuracy × Group interaction at each lead. The Group × Accuracy interaction was significant at each lead, although the effect was slightly less significant at Fz relative to FCz and Cz. To further parse the Accuracy × Group and Accuracy × Group × Lead interactions, the accuracy effect was examined separately for each group and each lead. For both patients and controls, the accuracy effect was significant at each lead, indicating that the ERN was significantly more negative than the CRN in both groups. Next, the group effect was examined separately for errors and corrects at each lead. Relative to the HC group, the SZ group had a significantly smaller ERN at FCz and Cz, but not at Fz, and a significantly larger (i.e., more negative) CRN at Fz, FCz, and Cz (Figure 3a).
For the comparison of the ESZ subsample to their age-matched controls, there were significant main effects of accuracy and lead, similar to those described for the SZ versus HC analysis. In addition, there were significant Accuracy × Group and Accuracy × Group × Lead interactions, which were parsed by examining the Accuracy × Group effects at each lead. The Accuracy × Group effect was significant at FCz and Cz, but not at Fz. Further examining the accuracy effect within each group and lead, both ESZ and HC groups showed significant accuracy effects at each lead, indicating that the ERN was significantly more negative than the CRN in both groups. Further follow-up analyses examined the group effect separately for ERN and CRN at each lead. Relative to HC, ESZ patients showed a significantly reduced ERN at Cz, but not at Fz or FCz, and a significantly larger CRN at Fz, FCz, and Cz (Figure 3a).
For the comparison of the CHR group with their age-matched controls, there were significant main effects of accuracy and lead, similar to those described for the SZ versus HC analysis. In addition, there was a marginally significant Accuracy × Group effect (p = .055) and a significant Accuracy × Group × Lead interaction, which were parsed by examining the Accuracy × Group effect separately for each lead. The Group × Accuracy interaction was significant at Cz, marginally significant at FCz (p = .055), and not significant at Fz. The Group × Accuracy interactions were further parsed at each lead by examining the accuracy effect separately for each group. For both CHR and HC, there were significant effects of accuracy at each lead indicating that the ERN was significantly more negative than the CRN in both groups. Further follow-up analyses examined the group effect separately for ERN and CRN at each lead. Relative to HC, CHR patients showed reduced ERN amplitudes at Cz and FCz but not at Fz, whereas the CRN did not differ between the groups (Figure 3a).
Table 2 presents the Pe ANOVA results for each patient–control group comparison. Summary plots in Figure 3b present the mean Pe amplitude at Cz for each of the patient and HC groups. None of the ANOVA results involving group or accuracy effects were substantially changed when reanalyzed as ANCOVAs with either parental SES or gender as covariates.
For the comparison of the full SZ sample with their age-matched controls, there was a significant group effect indicating that SZ had a reduced (less positive) Pe relative to HC, as well as a significant lead effect indicating that the Pe was larger at FCz and Cz relative to Pz. There was also a significant Group × Lead interaction, indicating that the SZ – HC difference was somewhat larger at fronto-central sites (FCz, Cz) than at posterior sites (Pz), although SZ exhibited a significantly smaller Pe at all leads relative to HC (Figure 3b).
For the comparison of the ESZ subsample with their age-matched controls, there were significant main effects of group and lead. In addition, there was a significant Group × Lead interaction, indicating that the Pe reduction in ESZ relative to HC, which was significant at each lead, was somewhat more pronounced at fronto-central relative to parietal leads (Figure 3b).
For the comparison of CHR patients to their age-matched controls, there was a significant main effect of lead showing the Pe to be greater at fronto-central relative to parietal sites. However, neither the group effect nor the Group × Lead interaction was significant, indicating normal Pe amplitude in CHR patients (Figure 3b).
There were no significant associations between age and ERN at any electrode in the full HC sample, although CRN amplitude significantly decreased (i.e., became less negative) with increasing age at Cz (r = .21, p = .02) and showed a similar trend at FCz (r = .15, p = .09). Pe amplitude significantly decreased (i.e., became less positive) with increasing age at FCz (r = −0.27, p < .005) and Cz (r =−0.27, p < .005), but not at Pz. ERN, CRN, and Pe amplitudes were each regressed on age in the full HC sample (n = 130) spanning the age range from 12 to 59 years. Linear normal aging effects, regardless of significance, were removed from the ERP data for all groups based on these HC regression models, as described in the Methods. Resulting age-corrected z-scores reflected the deviation (in SD units) of each subject’s ERP component amplitude from the value expected for a healthy individual of a given age.
To test the hypothesis that ERP measures of error processing are more abnormal in ESZ patients than in CHR patients while taking into account the age difference between the groups, CHR and ESZ patients were directly compared on their age-corrected z-scores for each ERP component at Cz, the lead where group abnormalities tended to be strongest (Figure 3c). Neither ERN nor CRN z-scores significantly differed between CHR and ESZ patients (p > .5). However, Pe z-scores were significantly reduced in the ESZ relative to the CHR patients (p < .01).
The ERN, CRN, and Pe components from lead Cz were regressed on the error rate, group (SZ vs. HC), and the Error Rate × Group interaction. Because error rate distributions were positively skewed in all groups, a log10 transform was applied to normalize the distributions prior to conducting the regression analyses. For the ERN regression on error rate, the Error Rate × Group interaction was not significant (p = .75), indicating similar slopes in both groups. Dropping the interaction term, the test of the common slope was highly significant (p < .001), indicating that larger (i.e., more negative) ERN amplitudes were associated with lower error rates. Covarying for error rate, the SZ versus HC group effect was not significant (p = .31). For the CRN regression on error rate, the slopes in the SZ and HC groups were not significantly different (p < .30). However, the common slope was significant (p = .014), indicating that more negative CRN amplitudes were associated with lower error rates, and the group effect was significant (p < .001), indicating that CRNs remained more negative in SZ than in HC even when controlling for error rate. For the Pe regression on error rate, the slopes significantly differed between the groups (p = .024). The slope was positive in HC, indicating that a higher error rate tended to be associated with a larger Pe (r = .18, p = .058), whereas the slope was slightly negative in the SZ (r = −.14, p = .21).
Similar regression models examined the relationships between the ERP component amplitudes and post-error slowing. For the ERN, the Group × Post-error slowing interaction showed a trend for the group slopes to differ (p = .059). In HC, greater post-error slowing was associated with a larger ERN (r = −.22, p = .02), whereas no such relationship was evident in SZ patients (r = .01, p = .97). For the CRN, the slopes significantly differed between the groups (p = .002). In HC (r = −.32, p = .001), but not in SZ (r = .03, p = .80), greater post-error slowing was associated with significantly larger (i.e., more negative) CRN amplitudes. For the Pe regression on post-error slowing, there was no significant slope difference between the groups (p = .22), nor was the common slope significant (p = .29).
Regression analyses in the CHR and HC groups examined the relationships between the ERP component amplitudes at Cz and error rate (log10 transformed). For the ERN, the Group × Error rate interaction was not significant (p = .91), indicating similar slopes in the two groups. Dropping the interaction term from the model, a significant common slope (p = .001) indicated that lower error rates were associated with more negative ERN amplitudes for both groups. Covarying for error rate, the group effect showed a trend (p = .085) for the ERN to be smaller in CHR patients than in HC. For the CRN and the Pe, the slopes did not differ between the groups (p > .24) and the common slopes were not significant (p > .27), indicating that CRN and Pe amplitudes were unrelated to error rates in the CHR and HC groups.
The ERP component amplitudes were similarly regressed on post-error slowing in the CHR and HC groups. For the ERN, there was a trend for the slopes to differ between the groups (p = .059). Greater post-error slowing was associated with more negative ERNs in the HC (r = −.26, p = .015), but not in the CHR group (r = .12, p = .42). For the CRN, the slopes did not differ between the groups (p = .57). After dropping the interaction term from the model, the common slope was significant (p = .008), indicating that greater post-error slowing was associated with more negative CRNs in both groups. Covarying for post-error slowing, the group effect on CRN amplitude was not significant (p = .74). For the Pe, the slopes did not differ between the groups (p = .40) and the common slope was not significant (p = .49), indicating no relationship with post-error slowing.
Given that duration of illness was significantly related to age in the full SZ sample (r = .93, p < .001), the relationship between illness duration and each ERP component was assessed using age-corrected ERP component z-scores from electrode Cz (where group effects tended to be largest). Illness duration was not significantly correlated with ERN (r = −.06, p = .50) or Pe (r = .11, p = .27) z-scores. However, illness duration showed a significant negative correlation with CRN z-scores (r = −.31, p = .001), indicating that abnormal increases in CRN amplitude (i.e., increased negativity) worsened with longer illness duration.
PANSS positive and negative symptom subscales were not significantly correlated with ERN, CRN, or Pe amplitudes in the full SZ sample. Based on prior studies suggesting that ERN reductions in schizophrenia were particularly evident in patients with the paranoid subtype (Kopp & Rist, 1999; Mathalon et al., 2002), we directly compared paranoid and nonparanoid subtype schizophrenia patients. No significant subtype differences were found for ERN, CRN, or Pe. In the CHR patients, SOPS positive and negative symptom subscales were not significantly correlated with ERN, CRN, or Pe amplitudes.
Consistent with prior reports, the present study showed that patients with schizophrenia, relative to healthy controls, have 1) a reduced ERN amplitude following commission errors in a choice–response task (Alain et al., 2002; Bates et al., 2002; Bates et al., 2004; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Mathalon et al., 2009; Morris et al., 2008; Morris et al., 2006), and 2) an increased CRN amplitude following correct responses (Alain et al., 2002; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Morris et al., 2008; Morris et al., 2006). In addition, our results extend previous findings by showing that this ERN reduction and CRN increase is evident in the early phases of schizophrenia (within 2 years of initial hospitalization or initiation of antipsychotic treatment), prior to the onset of chronicity-related sequelae. Furthermore, we found that reduced ERN amplitude, but not increased CRN amplitude, is present in patients at clinical high risk for psychosis. In contrast to previous studies (Alain et al., 2002; Bates et al., 2004; Kim et al., 2006; Mathalon et al., 2002; Morris et al., 2006), our results indicate that the Pe following the ERN on error trials is significantly reduced in schizophrenia patients, including the subset of early illness patients, but not in clinical high risk patients. All of these performance-related ERP abnormalities were present despite normal post-error slowing in all the patient groups, suggesting that patients were aware of their errors at some level. Normal post-error slowing in schizophrenia patients is consistent with some prior studies (Bates et al., 2002; Bates et al., 2004; Mathalon et al., 2002), but not others (Alain et al., 2002; Kerns et al., 2005).
None of the previously published ERP error-processing studies of patients with schizophrenia (Alain et al., 2002; Bates et al., 2002; Bates et al., 2004; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Mathalon et al., 2009; Morris et al., 2008; Morris et al., 2006) examined at what stage of the illness the performance-related ERP abnormalities emerged or whether they progressively worsened over the illness course. Accordingly, our study of schizophrenia patients with a wide range of illness durations, including an early illness subsample, represents a significant extension of prior studies. Our finding of reduced ERN early in the illness course, coupled with the absence of a correlation between duration of illness and ERN amplitude, suggests that reduced ERN is a non-progressive abnormality that is evident well before the sequelae of chronic illness emerge (e.g., chronic disability and medication exposure, longstanding social and occupational dysfunction). In contrast, while abnormal enhancement of the CRN was evident in the full schizophrenia sample and the early illness subsample, the magnitude of the CRN abnormality increased with illness duration, consistent with a progressive pathophysiological process that begins early in the illness. Although the nature of this progressive process is not clear, these results suggest that CRN-related response uncertainty (Coles et al., 2001) or response checking (Falkenstein et al., 2000) during cognitive tasks intensifies as the illness progresses, either as a function of neurocognitive decline or as a compensatory response to such decline. While abnormal reduction of the Pe was evident in both the full schizophrenia sample and the early illness subsample, suggesting that it is a nonprogressive marker of compromised error awareness (Endrass et al., 2007; Falkenstein et al., 1991; Hughes & Yeung, 2011; Leuthold & Sommer, 1999; Nieuwenhuis et al., 2001; O’Connell, et al., 2007), this conclusion is difficult to reconcile with the preponderance of prior studies showing normal Pe in schizophrenia (Alain et al., 2002; Bates et al., 2004; Kim et al., 2006; Mathalon et al., 2002; Morris et al., 2006).
In addition to showing that ERN, CRN, and Pe abnormalities are present in schizophrenia patients within the first 2 years of illness onset, the present study is the first to examine which of these electrophysiological error monitoring signals are abnormal prior to the onset of psychosis in clinical high risk patients. Although the CRN and Pe were normal in at-risk patients, suggesting that they may become abnormal during the transition to, or after the onset of, schizophrenia, the ERN showed a significant reduction in clinical high risk patients that was not significantly different from the reduction evident in early illness patients. These results are consistent with those from a study of pre-prodromal 9–12-year-old children exhibiting putative antecedents of schizophrenia (Laurens et al., 2010). The presence of an ERN abnormality in clinical high risk patients suggests that this neurophysiological dysfunction predates schizophrenia onset and may be a trait marker of the underlying risk for the disorder. However, whether reduced ERN amplitude predicts conversion to psychosis, and more specifically, schizophrenia, in clinical high risk patients awaits longitudinal follow-up data.
One methodological challenge associated with comparing young clinically at-risk patients and older early illness schizophrenia patients is that these groups typically differ in age. In order to detect differences between these groups that may reflect progressive pathophysiological processes, the effects of normal development and aging on the measure of interest must be taken into account. The problem with ANCOVA models is that the effect of age is estimated by pooling across the different groups, potentially removing pathological aging effects along with normal aging effects. Our approach to this challenge involves modeling the effects of normal development and aging in healthy controls, and using the resulting model to remove these effects from both the healthy control and patient groups. In the current study, we found significant age-relationships with the CRN and Pe in the healthy controls, but failed to find an age relationship with the ERN. Those studies that have documented increases in ERN amplitude during normal development have focused on age ranges from childhood to early adulthood (Davies, Segalowitz, Dywan, & Pailing, 2001; Mathewson et al., 2005; Santesso et al., 2006). The absence of such relationships in our sample may reflect the fact that our age range began in early adolescence and extended to middle age. Nonetheless, removal of normal aging effects, even nonsignificant ones, enabled a direct comparison of clinical high risk and early schizophrenia patients despite their age differences.
Several relationships were observed between behavioral performance measures and the ERP measures, providing some behavioral validation of the ERP components as reflections of performance monitoring. Greater post-error slowing was significantly related to larger ERN amplitudes in healthy controls, but not in the SZ or CHR patient groups. This correlation in healthy subjects is consistent with a number of prior reports (Debener et al., 2005; Gehring et al., 1993; Kerns et al., 2004; West & Travers, 2008) although some studies failed to find this relationship (Gehring & Fencsik, 2001; van Meel, Heslenfeldb, Oosterlaana, & Seargeanta, 2007) or showed the opposite relationship (Dudschig & Jentzsch, 2009). Post-error slowing was also related to larger CRN amplitudes in healthy subjects and clinical high risk patients, consistent with the view of post-error slowing as a strategic adjustment (Rabbitt & Rodgers, 1977) that is more likely during heightened response monitoring (reflected by larger CRNs, as discussed below). However, it should be noted that other interpretations of post-error slowing have been proposed and supported by empirical data, including the view that it reflects ongoing error processing that interferes with processing the subsequent trial (Dudschig & Jentzsch, 2009; Gehring & Fencsik, 2001; Welford & Levin, 1979) or orienting to an infrequent event (Notebaert et al., 2009). In any case, the absence of relationships between post-error slowing and the ERN or CRN in patients with schizophrenia suggests that illness-related processes uncouple these normal brain–behavior relationships.
Schizophrenia patients, clinical high risk patients, and healthy controls showed significant associations between larger ERN amplitudes and lower error rates, consistent with prior studies (e.g., (Falkenstein et al., 1991; Falkenstein et al., 2000; Gehring et al., 1995; Scheffers et al., 1996). Larger CRN amplitudes were also associated with lower error rates in schizophrenia patients and their age-matched controls, although this relationship was not evident in the clinical high risk patients and their controls. In light of the younger age distribution in clinical high risk patients and their controls, it is possible that the CRN’s correlation with error rate emerges sometime after adolescence. This correlation suggests that larger CRNs may reflect greater efforts to be vigilant during task performance or intensified response monitoring (Falkenstein et al., 2000), an interpretation that has also been invoked to account for enhanced CRN amplitudes in patients with obsessive–compulsive disorder (Endrass et al., 2007). Although the relationship between Pe amplitude and error rate significantly differed between schizophrenia patients and healthy controls, the correlations within each group were not significant. Moreover, the Pe was unrelated to error rate in the clinical high risk patients and their controls.
Among the factors that may contribute to ERN reductions in schizophrenia (and by extension, in clinical high risk patients), ACC dysfunction has been the most consistently considered (Alain et al., 2002; Bates et al., 2002; Bates et al., 2004; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Mathalon et al., 2009; Morris et al., 2008; Morris et al., 2006). This interpretation is based on 1) dipole modeling studies implicating the ACC as the generator of the ERN (Badgaiyan & Posner, 1998; Dehaene et al., 1994; Holroyd et al., 1998; Luu et al., 2000; Miltner et al., 2003), and 2) fMRI studies of error processing showing deficient ACC activation in schizophrenia (Becerril, Repovs, & Barch, 2011; Carter et al., 2001; Kerns et al., 2005; Laurens et al., 2003; Polli et al., 2008). Of note, in a previous multimodal ERP/fMRI study of error processing, we found schizophrenia patients to have reduced ERN amplitudes but normal fMRI ACC activation to errors (Mathalon et al., 2009), underscoring the dissociability of ERP and fMRI measures of specific cognitive processes. More generally, the ACC dysfunction implicated by these ERN abnormalities is consistent with other research demonstrating functional and structural ACC abnormalities in schizophrenia (Benes, 1993; Benes & Bird, 1987; Fornito, Yucel, Dean, Wood, & Pantelis, 2009; Minzenberg et al., 2009). Related to these ACC interpretations of abnormal ERN, the prominent Holroyd and Coles (2002) model relating the ACC’s ERN signal to transient reductions in dopamine release following outcomes that are worse than expected suggests that the reduced ERN in schizophrenia may reflect disruption of the dopamine pathways that subserve reinforcement learning and reward.
While these pathophysiological interpretations of ERN abnormalities in schizophrenia are compelling because of their links to the larger theoretical and empirical schizophrenia literature, our results also implicate the increased error rate in schizophrenia patients and clinical high risk patients, relative to healthy controls, as a possible contributor to their reduced ERN amplitudes. Not only did our results corroborate the well-established relationship between a higher error rate and a smaller ERN, they showed that once the error rate difference between the groups was taken into account, the abnormal reduction of ERN amplitude in the patients was no longer significant (although a trend persisted in the clinical high risk group). These results suggest the possibility that the ERN reduction in schizophrenia is simply attributable to their increased error rate and the tendency for higher rates to be associated with smaller ERNs. In consulting the prior literature to evaluate this possibility, it was striking that none of the prior studies showing reduced ERNs in schizophrenia (Alain et al., 2002; Bates et al., 2002; Bates et al., 2004; Kim et al., 2006; Kopp & Rist, 1999; Laurens et al., 2010; Mathalon et al., 2002; Mathalon et al., 2009; Morris et al., 2008; Morris et al., 2006) had explicitly conducted an analysis controlling for error rate, despite the fact that many of the studies reported significantly greater error rates in patients than controls (Bates et al., 2002; Kim et al., 2006; Mathalon et al., 2009; Morris et al., 2008; Morris et al., 2006). Given the caveats about conducting ANCOVA models when groups differ on the covariate (Miller & Chapman, 2001), we repeated our analyses on performance-matched subgroups of patients and healthy controls and again observed that the ERN difference between the groups was not significant. We believe it would be premature to conclude that the ERN reduction in schizophrenia is spurious based on our results, in part because the prior literature neither corroborates nor refutes our results, and in part because it is possible that the pathophysiological mechanisms that give rise to increased error rates on cognitive tasks in schizophrenia patients may be inextricably linked to the mechanisms that produce deficient error detection signals. This complex issue needs to be examined and disentangled in future schizophrenia ERN studies.
While the CRN was also correlated with error rate in our study, this relationship did not account for the CRN enlargement observed in the schizophrenia patients. This suggests that abnormal CRN enhancement in schizophrenia, a finding that has been replicated numerous times (Alain et al., 2002; Kim et al., 2006; Kopp & Rist, 1999; Mathalon et al., 2002; Morris et al., 2008; Morris et al., 2006) may reflect pathophysiological processes that are unrelated to deficits in performance accuracy per se. Given the prior report showing enhancement of the CRN in patients with lesions of the dorsolateral prefrontal cortex (DLPFC; Gehring & Knight, 2000), it seems likely that DLPFC dysfunction may contribute to the pathological enhancement of CRN in schizophrenia. This hypothesis is consistent with a large body of evidence implicating DLPFC dysfunction in schizophrenia (see Bunney & Bunney, 2000; Minzenberg et al., 2009). However, it is also possible that the CRN enhancement reflects an intensification of response monitoring or checking (Falkenstein et al., 2000) in schizophrenia patients in an effort to compensate for the cognitive impairments (e.g., in attention and cognitive control) that compromise their task performance. Indeed, a similar compensatory strategy may have contributed to the CRN enhancement in the patients with DLPFC lesions described by Gehring and Knight (2000).
Schizophrenia patients also showed a reduced Pe, contrary to our previous finding (Mathalon et al., 2002) and other findings in the literature (Alain et al., 2002; Bates et al., 2004; Kim et al., 2006; Morris et al., 2006). Although Pe has been suggested to reflect error awareness (Falkenstein et al., 1991), it was not related to post-error slowing in any group. To the extent that both Pe and post-error slowing might reflect error awareness, it is important to note that schizophrenia patients had smaller Pe but normal post-error slowing. That is, although Pe reductions suggest patients have a weakened sense of error awareness, normal post-error slowing suggests that the effects of error commission on subsequent behavior was intact. It is possible that the reduced Pe in schizophrenia patients reflects deficient neural processes associated with detection of infrequent events more generally (Arbel & Donchin, 2009), consistent with the widely replicated P300 amplitude deficits observed in schizophrenia (Ford, 1999; Jeon & Polich, 2003). A number of researchers have suggested that the Pe is a P300-like response to the detection of an error (Leuthold & Sommer, 1999; Nieuwenhuis et al., 2001; O’Connell et al., 2007), supporting this interpretation. Moreover, P300 reduction in schizophrenia is much less consistent in visual paradigms than auditory paradigms (Jeon & Polich, 2003), perhaps explaining the inconsistency of our Pe finding relative to other error monitoring studies using visual tasks. In any case, despite abnormal ERN, CRN, and Pe amplitudes, patients are still able to make use of the neural circuitry underlying these compromised components, or are able to recruit other compensatory neural mechanisms, to slow down after making an error.
Some prior studies have found ERN reductions in schizophrenia to be associated with more severe positive symptoms or to the paranoid illness subtype (Kopp & Rist, 1999; Mathalon et al., 2002; Morris et al., 2008). At least one study found reduced ERN to be associated with greater disorganization and psychomotor poverty (Bates et al., 2002). In the present study, we found no significant clinical correlations, similar to the report by Kim et al. (2006). Several other studies did not report clinical correlations (Alain et al., 2002; Mathalon et al., 2009; Morris et al., 2006). Thus, whether the ERN abnormalities are a general characteristic of schizophrenia or are more specifically associated with specific symptom domains remains unclear.
In all of the previous reports of ERN reduction in schizophrenia, the patients were treated with dopamine D2-receptor blocking antipsychotic medication. The confounding effect of medication in these studies is particularly concerning in light of the Holroyd and Coles (2002) model implicating dopamine pathways in ERN generation, as well as evidence that acute administration of a dopamine D2 antagonist reduces the ERN in healthy volunteers (Zirnheld et al., 2004). Accordingly, the fact that we observed an ERN reduction in antipsychotic-free clinical high risk patients suggests that the ERN reduction in schizophrenia is unlikely to be caused by antipsychotic medication.
In conclusion, this study indicates that the neurophysiological substrates of early error monitoring during cognitive tasks are compromised in schizophrenia across the illness course, and in patients with attenuated psychotic symptoms who are at risk for developing the full-blown disorder. To the extent that these error monitoring processes subserve learning and successful task performance, their compromise in schizophrenia may significantly contribute to the behavioral impairments patients experience when faced with cognitive tasks, and may further interfere with their ability to learn new skills. Whether the ERN abnormality in schizophrenia patients is simply a function of increased error rate is a critical question that must be pursued in future studies. In addition, it remains to be determined whether reduced ERN in clinical high risk patients predicts conversion to psychosis. This is important because improvement in our ability to detect which clinical high risk patients will convert to psychosis sets the stage for preventive intervention, allowing early treatment to be targeted to those patients who need it most.
This study was supported by National Institutes of Health–supported grants R01 MH076989, R01 MH058262, and K02 MH067967. It was also supported by Department of Veterans Affairs Merit Review and the National Alliance for Research on Schizophrenia and Depression. Drs. Perez, Ford, Woods, McGlashan, Srihari, Loewy, Vinogradov, and Mathalon and Mr. Roach report no competing interests.
Veronica B. Perez, Department of Psychiatry, University of California, San Francisco (UCSF) and San Francisco Veterans Administration Medical Center.
Judith M. Ford, Department of Psychiatry, UCSF, San Francisco Veterans Administration Medical Center, and Yale University.
Brian J. Roach, Department of Psychiatry, University of California, San Francisco (UCSF) and San Francisco Veterans Administration Medical Center.
Scott W. Woods, Department of Psychiatry, Yale University.
Thomas H. McGlashan, Department of Psychiatry, Yale University.
Vinod H. Srihari, Department of Psychiatry, Yale University.
Rachel L. Loewy, Department of Psychiatry, UCSF.
Sophia Vinogradov, Department of Psychiatry, University of California, San Francisco (UCSF) and San Francisco Veterans Administration Medical Center.
Daniel H. Mathalon, Department of Psychiatry, UCSF, San Francisco Veterans Administration Medical Center, and Yale University.